Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
October 22, 2021 08:22 ET
|
Athira Pharma, Inc.
-Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small...
Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
October 21, 2021 16:05 ET
|
Athira Pharma, Inc.
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas’s Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21,...
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
September 29, 2021 08:05 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
August 23, 2021 07:30 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
August 16, 2021 16:01 ET
|
Athira Pharma, Inc.
- Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LIFT-AD are actively recruiting; topline data of...
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
August 05, 2021 16:56 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
July 19, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
July 06, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Chief Operating Officer, Mark Litton, Assumes Day-to-Day Leadership Responsibilities of Company
June 17, 2021 17:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 17, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore...
Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy
June 14, 2021 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...